Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Market Reaction: Big Pharma's vaccine names dipped on Wednesday with Moderna, Inc. (NASDAQ:MRNA) ending the day down 2.78%, ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Moderna's Spikevax COVID vaccine brought in sales of $1.8 billion, up 3.5% over the previous year and handily beating analysts' average expectations of $1.38 billion. The company said it benefited ...

It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but ...

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting ...

It will be a big week ahead with dozens of major earnings releases, a Federal Reserve meeting, and the U.S. election.

Antiviral Immunoglobulin Market. The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

The 2024–2025 COVID-19 vaccines are recommended for everyone aged 6 months and older in the US to target the currently circulating SARS-CoV-2 strains, JN.1 and KP.2.

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...